US Pharma MarketingSandoz targets industry patent void with $322m Henlius deal
Sandoz targets industry patent void with $322m Henlius deal is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.
Source: Pharmaceutical Technology